Cellyan Biotechnology HKPD
NASDAQ HKPD
$0.41 +0.01 (+2.07%)
At close: Aug 21, 2026 · 4:00 PM EDT

Cellyan Biotechnology (HKPD) Liabilities and Shareholders Equity (2024 - 2026)

Cellyan Biotechnology (HKPD) posted quarterly Liabilities and Shareholders Equity of $9.6 million for Q3 2025, down 5.2% year-over-year from $10.2 million in Q3 2024, and up 2.3% quarter-over-quarter from $9.4 million in Q1 2025.

Cellyan Biotechnology (HKPD) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends

Cellyan Biotechnology (HKPD) has reported Liabilities and Shareholders Equity for 2 consecutive years, with $9.6 million the latest figure, recorded in Q3 2025.

  • In Q3 2025, Liabilities and Shareholders Equity fell 5.2% year-over-year to $9.6 million; the TTM figure through Sep 2025 stood at $37.9 million (changed N/A YoY), while the FY2025 annual figure was $9.4 million, up 8.65% from the prior year.
  • Liabilities and Shareholders Equity improved to $9.6 million in Q3 2025 per HKPD's latest filing, from $9.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $10.2 million in Q3 2024 and bottomed at $8.7 million in Q1 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Mckesson 102.57 Bn 97.41 Bn 3.69 Bn 88.33 Bn
2 Cencora 61.35 Bn 58.53 Bn 3.61 Bn 83.81 Bn
3 Cardinal Health 54.15 Bn 49.30 Bn 2.56 Bn 57.30 Bn
4 Henry Schein 10.05 Bn 9.89 Bn 1.10 Bn 11.38 Bn
5 Akso Health 671.90 Mn 671.70 Mn - 189.63 Mn
6 Edap Tms 154.62 Mn 133.07 Mn 7.34 Mn 74.55 Mn
7 Accendra Health 90.69 Mn 83.04 Mn 263.41 Mn 2.11 Bn
8 111 31.31 Mn -27.44 Mn 18.18 Mn 279.33 Mn
9 Cosmos Health 13.28 Mn 10.84 Mn 1.51 Mn 61.46 Mn
10 Cellyan Biotechnology 6.70 Mn 6.48 Mn - 12.84 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 12.84 Mn
Sep 30, 2025 9.63 Mn
Mar 31, 2025 9.42 Mn
Sep 30, 2024 10.16 Mn
Mar 31, 2024 8.67 Mn